Key points are not available for this paper at this time.
In a double-blind controlled study of 122 patients from four populations, amitriptyline produced the most and placebo the least amount of symptomatic improvement, with trimipramine slightly less efficacious than amitriptyline; general practice patients tended to improve the most and medical clinic patients the least. The authors suggest that amitriptyline may be more potent than trimipramine at equal dosages, as evidenced by its greater production of side effects, and that the small difference in clinical efficacy between the two drugs may thus be dosage related.
Rickels et al. (Sat,) studied this question.